Open AccessSuccessful treatment of high-risk gestational trophoblastic disease in a patient with intolerance to standard chemotherapy (clinical case)
Author(s) -
Г. М. Телетаева,
Е. А. Ульрих,
D.Kh. Latipova Latipova,
А. И. Семенова,
Е. В. Левченко,
D.G. Ulrikh Ulrikh,
Igor Berlev,
Т. Ю. Семиглазова,
S.A. Protsenko Protsenko,
А. Ф. Урманчеева
Publication year - 2021
Publication title -
opuholi ženskoj reproduktivnoj sistemy
Language(s) - English
Resource type - Journals
eISSN - 1999-8627
pISSN - 1994-4098
DOI - 10.17650/1994-4098-2020-16-3-67-71
Subject(s) - medicine , gestational trophoblastic disease , chemotherapy , disease , trophoblastic neoplasm , drug , gestational trophoblastic neoplasia , pregnancy , gestation , pharmacology , genetics , biology
Gestational trophoblastic disease is a rare tumor highly sensitive to systemic drug therapy. The standard regimens of chemotherapy of I and II lines for patients in the high-risk group for gestational trophoblastic disease are the EMA-CO, EMA-EP and TP/TE regimens, which have been demonstrated to be effective and require adherence to drug doses and intervals of administration. If these criteria are not met, the risk of developing resistance with an unfavorable outcome for patients is extremely high. The situation is extremely difficult when a patient has an absolute allergic intolerance to one of the components of standard regimens, which is presented in a clinical case.